论文部分内容阅读
30例经病理确诊的颅内恶性肿瘤应用V_(M-26)Me-CCNU联合化疗方案,5d为1个周期,每周期相隔4周,连续4个周期.观察指标包括临床症状和体征,头颅CT或MRI检查.随访时问4～12个月以上.对照组3O例,系同期内经病理确诊的恶性脑肿瘤患者,作随机抽样对照,所用的联合化疗方案为VP_(16)-Me-CCNU,其用药疗程、周期、观察指标及随访期限均与治疗组相同.结果表明,治疗组与对照组的总有效率分别为63.3%和36.6%,(X~2=4.27,P<0.05),说明V_(M-26）-Me-CCNU序列治疗颅内恶性肿瘤是一种安全有效的化疗方案.
Thirty patients with pathologically confirmed intracranial malignancy were treated with V (M-26) Me-CCNU combined with chemotherapy, 5 days for one cycle and 4 cycles for each cycle for 4 consecutive weeks.Observation included clinical symptoms and signs, CT or MRI were followed up for more than 4 to 12 months.Over 30 patients in the control group were randomly selected from patients with malignant brain tumors diagnosed by pathology during the same period.The combination regimen used was VP 16 -Me-CCNU The results showed that the total effective rates of the treatment group and the control group were 63.3% and 36.6%, respectively (X ~ 2 = 4.27, P <0.05) It indicated that the V_ (M-26) -Me-CCNU sequence was a safe and effective chemotherapy for the treatment of intracranial malignant tumors.